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Thymic epithelial tumors (TETs) are rare primary mediastinal tumors arising from thymic epithelium. Their rarity and com-
plexity hinder investigations of their causes and therapy development. Here, we summarize the existing knowledge
regarding medical treatment of these tumors, and thoroughly review the known genetic aberrations associated with TETs
and the present status of potential biological treatments. Epidermal growth factor receptor (EGFR), stem-cell factor recep-
tor, insulin-like growth factor-1 receptor (IGF1R), and vascular endothelial growth factors (VEGF-A, VEGF-B, and VEGF-2)
are overexpressed in TETs. EGFR overexpression in TETs is associated with higher stage, and IGF1R overexpression has
poor prognostic value. Data indicate that anti-IGF1R monoclonal antibodies, and inhibitors of angiogenesis, somatostatin
receptors, histone deacetylase, mammalian target of rapamycin, and cyclin-dependent kinases may be active against
TETs. Continued investigations in this ﬁeld could lead to advancement of targeted and biological therapies for TETs.
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thymic epithelial tumors
Epithelial tumors of thymus are rare cancers and epidemiologic-
al data are limited.
In Europe, the incidence rate (period of diagnosis 1995–
2002) was 1.4 per 1 000 000 for thymoma (T) [1, 2]. In United
States, the overall incidence of T was 1.3 per 1 000 000 person
years [3]. The majority of patients with T present with early-
stage disease, whereas nearly three-quarters of patients with
thymic carcinoma (TC) present with locally advanced or meta-
static disease. Five-year survival varied signiﬁcantly among
patients with T compared with TC: more than 80% and ∼40%,
respectively [4, 5]. In detail, 5-year survival was 88% [95% conﬁ-
dence interval (CI) 59.4–96.9], 83% (95% CI 64–93), 82% (95%
CI 61–92), 82% (95% CI 67–91), 54% (95% CI 33–70), 38%
(95% CI 20–55) for T (A, AB, B1, B2, B3, and C), respectively
[5]. Five-year survival varied also by stage: from 80% to 90% for
stage I and II, from 60% to 70% for stage III, from 44% to 55%
for stage IV [4–6].
According to the World Health Organization (WHO) histo-
logical classiﬁcation, T includes ﬁve entities (types A, AB, B1,
B2, and B3) and is the most common primary anterior medias-
tinal mass, whereas TC is much more rare but much more likely
to spread [7]. The causes of thymic epithelial tumors (TETs)
remain unknown, but our general knowledge of the involved
aberrant pathways is improving. The thymus is the site of
T-cell maturation, playing a central role in adaptive immunity,
and patients with TETs often also present systemic autoimmune
syndromes, including myasthenia gravis autoantibodies to
acetylcholine receptors, pure red cell aplasia (PRCA), and hypo-
gammaglobulinemia. The natural history of the disease is
usually unpredictable, ranging from asymptomatic incidentally
discovered disease with an indolent course to aggressive malig-
nant tumors.
The rarity of this tumor type has precluded it from large phase
II and III clinical trial investigations, and new drug development
for TET treatment has progressed slowly. Systemic chemotherapy
currently represents the standard of care for metastatic or inoper-
able refractory/recurrent disease, but there remains a lack of stand-
ard treatment after ﬁrst-line failure. In the last decade, several
targeted agents have been investigated and the success rates have
varied. At present, research on the use of targeted agents in TETs
is ongoing. In the present narrative review, we emphasize the most
relevant current information regarding the medical treatment of
advanced TETs, with a focus on targeted therapies.
chemotherapy
Patients with advanced TETs are candidates for chemotherapy.
Adjuvant chemotherapy is not recommended for radically
resected (R0) stage I–II TETs. Induction therapy followed by
surgery may be useful for thymic malignancies that are initially
considered unresectable [8]. Platinum-based combinations
remain the standard of care.
Due to the rarity of TETs, published experiences with chemo-
therapy are limited to anecdotal case reports, retrospective ana-
lyses, and small prospective trials, leaving room for debate
regarding treatment decisions. Ts are chemotherapy-sensitive,
with an average of two thirds of patients showing an objective
response rate (ORR) and one-third showing a complete response
(CR), and durable remissions produced in patients with advanced
or metastatic Ts. However, the median duration of response
varies dramatically among studies, ranging from 1 to more than
7 years. Chemosensitivity has been observed to vary according
to the different histological subtypes, with TC considered the
least responsive. Table 1 depicts the designs and main outcomes
of previous studies of the use of chemotherapy in TETs.
single-agent chemotherapy
There are few documented experiences with the use of single-
agent chemotherapy (cisplatin, ifosfamide, and pemetrexed) for
patients with advanced T. The Eastern Cooperative Oncology
Group (ECOG) evaluated cisplatin (50 mg/m2 every 3 weeks) in
patients with advanced/metastatic T in a prospective phase II
trial. In this study, 21 patients were eligible for assessment, of
whom 2 (10%) demonstrated partial remission (PR) and none
showed CR. Median overall survival (OS) was 76 weeks, with a
2-year survival rate of 39% [9].
British investigators retrospectively examined the use of ifos-
famide as single-agent therapy for T, and reported that the most
common toxicities were nausea, vomiting, and leucopenia.
Among the 13 assessable patients, the ORR was 46.2%, with ﬁve
cases showing CR and one PR. Two of the patients had TC and
showed stable disease (SD) as the best response to therapy. The
median duration of CR was 66 months, and the estimated
5-year survival rate after ifosfamide therapy was 57% [10].
A phase II study evaluated the administration of pemetrexed
500 mg/m2 every 3 weeks for a maximum of six cycles among
27 patients with previously treated, unresectable, stage IVA or
stage IVB recurrent thymic malignancies [11]. Results were
reported only as abstract: of the 23 fully assessable patients, 2
showed CR and 2 PR. Each of these four responding patients
had stage IVA disease. Among the total population, median
time to progression (TTP) was 45 weeks (45.4 weeks for T
versus 5.1 weeks for TC), and OS was 29 months. Toxicity was
mild, with no patient experiencing grade IV adverse events.
Overall, the preliminary available data indicate that single-agent
pemetrexed could be an active agent in a heavily pretreated
population of patients with recurrent Ts, but has limited activity
in TCs.
polychemotherapy
Cisplatin-based polychemotherapy currently represents the
standard of care for TETs. The role of anthracyclines is import-
ant; a recent meta-analysis of clinical trials and retrospective
investigations compared the efﬁcacy of platinum with anthracy-
clines versus platinum with nonanthracycline-based chemother-
apy in both Ts and TCs, showing a 69.4% response rate [95%
conﬁdence interval (CI) 63.1% to 75.0%] for platinum with
anthracycline-based chemotherapy and 37.8% (95% CI 28.1% to
48.6%; P < 0.0001) for platinum with nonanthracycline-based
chemotherapy for Ts whereas the response rates with anthracy-
cline-based and nonanthracycline-based chemotherapy for TCs
were similar (40.2% versus 41.2%; P < 0.89) [31].
In the early 1990s, the ADOC regimen (doxorubicin, cis-
platin, vincristine, and cyclophosphamide) was tested in the
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Table 1. Single-agent and combination chemotherapies for TETs
Reference Study
population (N)
Study treatment Main outcomes Comment(s)
Single-agent therapy
Bonomi et al. [9]
ECOG
21 Cisplatin ORR 10% (2 PR)
OS 76 weeks
2-year surgery 39%
Phase II trial
Highley et al. [10] 15 Ifosfamide ORR 46.2% (5 CR and 1
PR)
5-year surgery 57%
Retrospective series
Loehrer et al. [11] 27 Pemetrexed ORR 17%
T-group ORR 25% (2 CR
and 2 PR)
TC-group ORR 9% (1 PR)
OS 29 months
Phase II trial
Second line
Platinum and anthracycline-based regimens
Fornasiero et al. [12] 32 Doxorubicin, cisplatin, vincristine,
cyclophosphamide (ADOC)
ORR 91%
CR 47%
TTP 11 months
OS 15 months
Retrospective series
All patients with T
Rea et al. [13] 16 Doxorubicin, cisplatin, vincristine,
cyclophosphamide (ADOC) (+S)
ORR 100%
CR 43%
3-year surgery 70%
OS 66 months
Retrospective series
All patients with T
Koizumi et al. [14] 8 Doxorubicin, cisplatin, vincristine,
cyclophosphamide (ADOC)
ORR 75%
OS 19 months
Retrospective series
All patients with TC
3 patients in second
line
Berruti et al. [15] 16 Doxorubicin, cisplatin, vincristine,
cyclophosphamide (ADOC) (+S ± RT)
ORR 81%
CR 12%
TTP 33 months
OS 47 months
Phase II
All patients with T
Loehrer et al. [16]
ECOG-SWOG-SEC SG
30 Doxorubicin, cisplatin, cyclophosphamide (PAC) ORR 50%
CR 10%
TTP 18 months
OS 38 months
Phase II
29 patients with T
Loehrer et al. [17] 23 Doxorubicin, cisplatin, cyclophosphamide (PAC)
(+RT)
ORR 70%
CR 22%
TTP 93 months
OS 93 months
5-year surgery 52%
Phase II
21 patients with T
Shin et al. [18] 13 Doxorubicin, cisplatin, cyclophosphamide
(PAC + Prednisone (+RT + S)
ORR 92%
CR 25%
PR 67%
7-year surgery 100%
7-year DFS 73%
Phase II
All patients with T
Kim et al. [8] 22 Doxorubicin, cisplatin, cyclophosphamide
(PAC + Prednisone (+RT + S)
ORR 77%
CR 14%
PR 63%
5 year surgery 95%
7-year surgery 77%
Phase II
All patients with T
Yokoi et al. [19] 14 Doxorubicin, cisplatin, methylprednisolone
(CAMP) (±RT or S)
ORR 92%
OS 30 months
Retrospective series
Macchiarini et al. [20] 7 Cisplatin, epirubicin, etoposide (PEpE) (+S + RT) ORR 100%
2-year surgery 80%
Phase II
All patients with T
Lucchi et al. [21] 36 Cisplatin, epirubicin, etoposide (PEpE) (+S ± RT) OS 113 months
10-year surgery 46% (stage
III)–48% (stage IVA)
Retrospective series
12 patients not
treated with CT
Continued
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ﬁrst-line setting, and showed an ORR of 92% and an OS of 15
months [12]. Similar results were shown in successive retro-
spective series in both T [13] and TC [14]. A phase II trial of 16
patients treated with ADOC regimen conﬁrmed prospectively
its activity: ORR was 81% with a DFS of 33.2 months and a
median OS of 47.5 months [15].
Another study demonstrated that a three-drug combination
of cisplatin, doxorubicin, and cyclophosphamide (PAC or CAP)
was associated with an ORR of 50% and an OS of 38 months
[16]. The European Organization for Research and Treatment
of Cancer investigated cisplatin and etoposide in 16 patients,
and reported an ORR of 56% and an OS of 4.3 years [22].
Notably, another study in 28 patients found that the addition of
ifosfamide to this doublet (the so-called VIP schedule) resulted
in PR in 32% of cases [24]. Carboplatin (area under the curve 6)
plus paclitaxel (225 mg/m2) administered every 3 weeks was
demonstrated to have modest clinical beneﬁt, showing an ORR
of 42.9% and PFS of 16.7 months among patients with T, and an
ORR of 21.7% and PFS of 5.0 months for those with TC [28].
Median OS was not reached among the patients with T, and was
20.0 months in subjects with TC.
second-line chemotherapy
Second-line chemotherapy includes etoposide, ifosfamide,
pemetrexed, 5-FU or analogs, gemcitabine, and paclitaxel. A
phase II trial investigated the administration of capecitabine
(1300 mg/m2 on days 1–14) and gemcitabine (1000 mg/m2 on
days 1 and 8) every 3 weeks in 15 pretreated patients, and the
preliminary results demonstrated an ORR of 40% with accept-
able toxicity, and 1- and 2-year survival rates of 80% and 67%,
respectively [32]. The ﬁnal analysis of the trial results was re-
cently presented at the ASCO annual meeting [33]: among 30
patients, 3 showed CR and 8 PR, with a PFS of 11 months.
Table 1. Continued
Reference Study
population (N)
Study treatment Main outcomes Comment(s)
Platinum-based regimens
Giaccone et al. [22]
EORTC
16 Cisplatin + etoposide (PE) ORR 56%
PFS 2.2 years
OS 4.3 years
Phase II
All patients with T
Mineo et al. [23] 33 Cisplatin + etoposide (PE) (+S + RT) ORR 37%
OS 30 months
5-year surgery 37%
Retrospective series
All patients with T
Loehrer et al. [24]
ECOG
34 Cisplatin + ifosfamide + etoposide (VIP) ORR 32%
OS 32 months
Phase II
Grassin et al. [25] 18 Cisplatin + ifosfamide + etoposide (VIP) ORR 25%
1-year surgery 94%
2-year surgery 78%
Phase II
Igawa et al. [26] 11 Carboplatin + paclitaxel ORR 36%
PFS 8 months
OS 23 months
Retrospective series
All patients with TC
Furugen et al. [27] 16 Carboplatin + paclitaxel ORR 37%
CR 12%
PR 25%
PFS 9 months
OS 49 months
Retrospective series
All patients with TC
Lemma et al. [28] 46 Carboplatin + paclitaxel ORR 42.9 (T)
ORR 21.7% (TC)
PFS 16.7 months (T)
PFS 5 months (TC)
OS 20 months (TC)
Phase II
23 patients with TC
OS not reached for T
Takeda et al. [29]
WJOG
40 Carboplatin + paclitaxel ORR 36%
PFS 8 months
1-year surgery 85%
2-year surgery 71%
Phase II
All patients with TC
Okuma et al. [30] 9 Cisplatin + irinotecan ORR 56%
PFS 8 months
OS 34 months
1-year surgery 78%
2-year surgery 565
Retrospective series
All patients with TC
ORR, overall response rate; OS, overall survival, CR, complete response; TTP, time to progression; PR, partial response; PFS, progression-free survival;
RT, radiotherapy; EORTC, European Organization for Research and Treatment of Cancer.
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molecular aberrations in TETs and
biological treatment approaches
The molecular aberrations underlying thymic malignancies are
poorly understood and lack valid preclinical models. The hetero-
geneity among subtypes and the rarity of the disease make it difﬁ-
cult to investigate relevant genetic alterations. Insights into the
biology of thymic tumors have mainly been attained based on an-
ecdotal clinical responses to targeted therapies [34–39]. Some
studies have investigated the possibility of exploiting these
insights to develop biological and targeted therapies for TETs.
These include inhibitors of stem-cell factor receptor (SCFR/KIT/
CD117), vascular endothelial growth factor (VEGF) receptor
(VEGFR), epidermal growth factor receptor (EGFR), insulin-like
growth factor-1 receptor (IGF1R), somatostatin (SST) receptors,
histone deacetylase (HDAC), tropomyosin-related kinase A
(TrkA), cyclin-dependent kinase (CDK), sarcoma protein (Src),
and mammalian target of rapamycin (mTOR).
More recently, data using array-comparative genomic hybrid-
ization and next generation sequencing have identiﬁed a number
of genetic alterations providing a new perspective of the molecular
aberrations that differentiate indolent thymomas from more ag-
gressive thymomas and TCs.
In particular, the recurrent GTF2I mutations, which encodes
TFII-I, occur with a very high frequency in indolent tumors and
represent a marker of favorable prognosis that may be useful in
the classiﬁcation of these rare tumors [40].
The molecular markers BCL2 and CDKN2A may be of poten-
tial value in diagnosis and prognosis of TETs and preclinical
studies suggested that deregulated antiapoptotic BCL2 family
proteins may represent suitable targets for TET treatment [41].
Furthermore, recurrent mutations of KIT were found [40, 42];
however, their clinical role is still to be deﬁned.
Table 2 summarizes the design and the main outcomes of
available studies on targeted therapies for advanced TETs.
epidermal growth factor receptor
EGFR is one of the most studied biomarkers in epithelial
cancers. Several studies have used immunohistochemistry (IHC)
to investigate EGFR expression levels in thymic tumors [62–69].
EGFR is reportedly overexpressed in 70% of Ts and 53% of TCs,
with higher EGFR staining signiﬁcantly associated with stage
III–IV tumors. EGFR copy number seems signiﬁcantly ampli-
ﬁed in type B3 Ts. The degree of this EGFR ampliﬁcation, as
measured by ﬂuorescence in situ hybridization, poorly correlates
with EGFR overexpression but is signiﬁcantly associated with
stage II–IV tumors [70]. EGFR mutations are rare in thymic
malignancies [39, 43, 62, 66, 68]. Among 158 analyzed tumors,
only 3 EGFR mutants were found, all of which were missense
mutations in exon 21 (2 cases of L858R and 1 case of G863D).
No mutations were detected in exons 18 and 19. There is no
reported correlation between EGFR expression and EGFR muta-
tional status.
A phase II trial, available only as an abstract, examined the
results of geﬁtinib administration (250 mg orally daily) among
26 pretreated patients with stage IV TETs achieving only one
partial response. [43]. It is likely that thymic tumors rarely
respond to EGFR inhibitors due to the low frequency of EGFR-
activating mutations in these tumors. Another abstract de-
scribed a phase II trial included 18 chemorefractory patients
with limited clinical beneﬁt, and assessed the effects of adminis-
tering a combination of erlotinib (150 mg PO daily) and bevaci-
zumab (15 mg/kg i.v. every 3 weeks) without any interesting
results. [44]. Only two case reports described activity of cetuxi-
mab in heavily pretreated recurrent Ts [38, 71]. An ongoing
phase II trial is evaluating cetuximab in combination with a
CAP regimen for treatment of unresectable thymomas (clinical-
trials.gov NCT01025089). Although single-case observations
suggest that EGFR targeting may be effective in some patients,
two clinical phase II studies using erlotinib and geﬁtinib in a
total of 44 patients resulted in no complete remission and only
two partial responses. Based on available evidence, the role of
inhibiting EGFR in T and TC seems promising but it is still to
be clariﬁed.
stem-cell factor receptor
KIT is a transmembrane growth factor with tyrosine kinase ac-
tivity, and its ligand is the stem-cell factor (SCF). KIT is overex-
pressed in 2% of Ts and 79% of TCs [72]. Although 80% of TCs
reportedly overexpress KIT protein, only 9% show KIT muta-
tions [73], with a V560 deletion detected in two cases, one mis-
sense mutation in exon 11 (L576P substitution), a D820E
mutation found in a patient responding to sorafenib, and an
H697Y mutation in exon 14 in a case with high sensitivity to
sunitinib in vitro. Among the known mutations, V560 deletions
and the L576P substitution are sensitive to imatinib [34].
Phase II trials evaluated the effects of imatinib in B3 Ts and
TCs—which were selected based on KIT staining by IHC rather
than genotyping—and reported negative results [47]. A small
phase II trial evaluated imatinib (600 mg PO daily) in seven
patients with TETs, and found that two patients had SD and ﬁve
progressed, the median OS was 4 months, and median TTP was
2 months. Samples from four patients were analyzed by IHC,
which revealed KIT expression in one sample. Three samples
were analyzed for mutations in the KIT or PDGFRA genes,
revealing no mutations. The authors concluded that imatinib
has no major activity in this tumor; however, these results may
have been inﬂuenced by the small number of patients and lack
of selection criteria [45]. A second trial investigated imatinib ad-
ministration in 11 patients with pretreated, advanced, unresectable
TCs. KIT expression was conﬁrmed by IHC staining in nine
patients, and PDGFR in two patients. No objective response was
reported in the abstract [46]. Finally, a third phase II trial of imati-
nib (400 mg PO daily) in 15 pretreated patients reported no re-
sponse, with a median PFS of 3 months. None of the patients
harbored a known KIT activating mutation. Three of the included
patients had TCs, of whom two presented KIT expression on
IHC [47].
insulin-like growth factor-1 receptor
IGF1R is a transmembrane receptor that is frequently overex-
pressed in squamous cell carcinomas, and that apparently plays
roles in multiple processes related to oncogenesis. IGF1R can
form heterodimers with EGFR, which promotes resistance to
EGFR inhibitors. In a cohort of 63 thymic tumors, IGF1R
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Table 2. Targeted therapies in TETs
Reference Study population (N) Study treatment Main outcomes Comment(s)
EGFR inhibitors
Kurup et al. [43] 26 Gefitinib ORR 1%
14 SD
TTP 4 months
Phase II
Bedano et al. [44] 18 Erlotinib + Bevacizumab ORR 0%
11 SD
Phase II
KIT inhibitors
Giaccone et al. [45] 9 Imatinib ORR 0%
2 SD
OS 4 months
TTP 2 months
Phase II
7 patients with TC
Salter et al. [46] 11 Imatinib ORR 0% Phase II
All patients with TC
Palmieri et al. [47] 15 Imatinib ORR 0%
1 SD
PFS 3 months
Phase II
3 patients with TC
IGF1R inhibitors
Haluska et al. [48] 1 Figitumumab SD Phase I
Rajan et al. [49] 49 Cixutumumab ORR 10%
33 SD
Phase II
All patients with TC
Angiogenesis inhibitors
Bedano et al. [44] 18 Erlotinib + Bevacizumab ORR 0%
11 SD
Phase II
Isambert et al. [50] 1 Aflibercept + Docetaxel PR Phase I
Thomas et al. [51]
NCT01621568
23 TCs/16 Ts Sunitinib • TC
• ORR 26%15 SDPFS 6.7 months
OS 16.3 months
• T
ORR 6%
12 SD
PFS 8.5 months
OS
Phase II
Fiedler et al. [52] 4 SU014813 2 PR (PFS 15.3 and 9.0 months) Phase I
Azad et al. [53] 1 Motesanib SD Phase I
SSTR inhibitors
Palmieri et al. [54] 16 Octreotide + Prednisone ORR 37%
OS 15 months
Phase II
Loehrer et al. [55] 38 Octreotide ± Prednisone ORR 30% Phase II
Longo et al. [56] 12 Long-acting octreotide 3 PR (25%)
5 SD (42%)
PFS 8 months
Retrospective experience
HDAC inhibitors
Steele et al. [57] 1 Belinostat SD Phase I
Giaccone et al. [58] 41 Belinostat 2 PR
25 SD
Phase II
16 patients with TC
CDK inhibitors
Besse et al. [59]
NCT01011439
30 Milciclib maleate 1 PR
13 SD
PFS-3 rate 46.7%
Ongoing
Phase II
Src inhibitors
Wakelee et al. [60] 21 Saracatinib No efficacy Phase II
7 patients with TC
mTOR inhibitors
Zucali et al. [61]
NCT02049047
35 Everolimus 1 CR
3 PR
21 SD
Ongoing
Phase II
ORR, overall response rate; SD, stable disease; TTP, time to progression; OS, overall survival; PFS, progression-free survival; PR, partial response; CR,
complete response.
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overexpression was found to be more frequent in TCs (86%) than
in Ts (43%), and was signiﬁcantly associated with EGFR overex-
pression [74]. Girard et al. did not ﬁnd IGF1R overexpression to be
related to TTP. However, Zucali et al. investigated TETs and
reported that among IGF1R overexpression carries a poor prog-
nostic value for OS, as well as for TTP among primary tumors
[75].
A phase I dose-escalation study in patients with refractory
solid tumors reported that the anti-IGF1R monoclonal antibody
ﬁgitumumab showed clinical activity lasting more than 1 year in
a case of refractory T [48]. A very recent multicenter, open-
label, phase II trial tested the administration of cixutumumab
(IMC-A12, 20 mg/kg i.v. every 3 weeks until disease progression
or unacceptable toxicity) in 49 pretreated patients with TETs
(37 Ts and 12 TCs) [49]. Among patients with Ts, 5 showed PR
and 28 SD, whereas in the TC cohort, only 5 patients experi-
enced SD. However, a relevant number of toxicities were
observed such as: hyperglycemia (10%), lipase elevation (6%),
and weight loss, tumor pain, and hyperuricemia (4% each).
Notably, nine T patients (24%) developed autoimmune condi-
tions during treatment, including ﬁve new-onset disorders, the
most common of which was PRCA.
vascular endothelial growth factors
and VEGF receptors and angiogenesis
inhibitors
VEGF and VEGFR are the most potent proangiogenic mole-
cules, and VEGF-A, VEGFR-1, and VEGFR-2 are overexpressed
in both Ts and TCs [76]. Microvessel density and VEGF expres-
sion levels have been shown to correlate with tumor invasion
and clinical stage in TETs [77]. Increased serum levels of VEGF
are observed in patients with TCs but not in those with Ts [78].
While it is known that TETs overexpress VEGF and VEGFRs,
limited data exist regarding the efﬁcacy of angiogenesis inhibi-
tors in these tumors. Isambert et al. conducted a phase I trial
[50] and reported that a patient with T experienced a PR follow-
ing administration of the combination of aﬂibercept (a soluble
receptor that binds VEGF-A; also called VEGF trap) and doce-
taxel. Multikinase inhibitors may also be of interest for targeting
angiogenesis. A patient who presented a missense mutation in
exon 17 (D820E) of KIT reportedly showed PR following sorafe-
nib treatment [79]. Another patient showed prolonged disease
stability of about 9 months in a tumor that lacked mutations but
that was demonstrated by IHC to highly express KIT, p53, and
VEGF [35]. The activity of sorafenib in TETs was additionally
conﬁrmed in a third case report [80] that described a 50% re-
duction of tumor size lasting for 18 months in patient with a
KIT-negative TC. A phase II trial investigated sunitinib admin-
istration after failure of platinum-based chemotherapy, and the
preliminary data were presented at the 2014 ASCO meeting
[51]. Among 23 evaluable TCs, 6 (26%) showed PR and 15
(65%) SD, with 6.7 of PFS and 16.3 months of OS at 13.9
months of follow-up. In contrast, of the 16 Ts, only 1 (6%)
showed PR and 12 (75%) had SD, with a PFS of 8.5 months and
an OS of 16.3 months after 12.7 months of follow-up. KIT
mutations were absent in 20 tumors assessed, which included 11
TCs and 4 cases that showed PR. In conclusion, beyond the
inhibition of KIT, ‘sunitinib’ and ‘sorafenib’ also inhibit
VEGFR-1, VEGFR-2, and VEGFR-3 at the nanomolar range:
the effect of these drugs, especially in KIT-wild-type thymic
tumors may then be partially related to an antiangiogenic effect.
In phase I trial of SU14813—a multitargeted tyrosine kinase
inhibitor (VEGFRs, PDGFRs, KIT, and FLT-3)—four patients
with Ts were treated, and two experienced PR with PFS of 15.3
and 9.0 months [52]. Similar to sunitinib and sorafenib, the
VEGFR-1/2/3 inhibitor motesanib diphosphonate (AMG-706)
reportedly controlled the growth of an advanced T refractory to
chemotherapy for 12 months [53]. A phase II trial tested bevaci-
zumab in combination with erlotinib, and found no tumor re-
sponse in 11 Ts and 7 TCs [44]. Interestingly, despite the large
tumor burden of thymic tumors and the frequent abutment to
mediastinal vascular structures, no hemorrhagic side-effects
have been reported with the use of these drugs.
somatostatin receptor inhibitors
Octreotide, an octapeptide SST analog with high afﬁnity for
SST2 subtype receptor, has been demonstrated to have an in-
hibitory effect in thymic epithelial cells in vitro [81]. A phase II
trial enrolled 16 patients treated with s.c. octreotide (1.5 mg
daily) plus prednisone (0.6 mg/mq/day orally for 3 months, 0.2
mg/kg/day orally during follow-up). The ORR was 37% and the
OS was 15 months [54]. A similar trial was conducted by ECOG
in patients with advanced, unresectable, octreotide-scan-positive
TETs [55] in which octreotide effect was evaluated alone for two
cycles and then, if no objective response was observed, in associ-
ation with prednisone. Thirty-eight patients (32 Ts, 5 TCs, and
1 thymic carcinoid) received octreotide 0.5 mg s.c. three times
daily for up to 1 year. Among these 38 patients during treatment
with octreotide alone, 4 (10.5%) showed PR. Among the 21
patients who received prednisone in addition to octreotide, 2
CRs and 6 PRs were noted. The overall ORR was 30.3%, and the
1- and 2-year survival rates were 86.6% and 75.7%, respectively.
Eight patients experienced grade 4 or 5 toxicity, including one
death that occurred secondary to grade 5 infection without neu-
tropenia. In a more recent retrospective experience, 12 TET
patients were treated with long-acting octreotide (20 mg i.m.
every 2 weeks) [56]. In total, 3 PR (25%) and 5 SD (42%) were
reported, with a mean PFS of 8 months (range, 3–21 months).
Treatment compliance and tolerability were judged to be good.
An ongoing phase II trial is currently evaluating the effect of
pasireotide (SOM230 LAR) in a dosage of 60 mg i.m. adminis-
tered every 4 weeks among adult patients with inoperable or
metastatic T (clinicaltrials.gov NCT02021942).
histone deacetylase inhibitors
In a phase I study of the pan-HDAC inhibitor belinostat
(PXD101), a patient with T showed a tumor reduction that lasted
for 17 months of treatment [57]. A phase II trial studied the
administration of belinostat (1 g/m2 on days 1 through 5, every
3 weeks) to 41 patients (25 Ts and 16 TCs), and reported PR in
2T patients, along with 25 SD and 13 PD. TTP was 174 days and
OS was 575 days. Treatment was well tolerated, with nausea,
vomiting, and fatigue shown to be the major adverse effects [58].
An ongoing phase I/II trial is investigating belinostat in
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combination with CAP as ﬁrst-line therapy for advanced or recur-
rent thymic malignancies (clinicaltrials.gov NCT 01100944).
tropomyosin-related kinase A and
cyclin-dependent kinases inhibitors
Kim et al. [82] used IHC staining to evaluate Trk expression in
99 patients with TET, and found cytoplasmic TrkA immunor-
eactivity in all tumors except one TC, whereas no tumors showed
TrkB or TrkC immunoreactivity. Their results also showed that
expression of the neurotrophin receptor p75(NTR) in Ts was
correlated with staging.
CDK proteins controlling cell cycle G1-S phase transition
may be altered through p16INK4 loss in Ts [83]. Through in-
hibition of CDK4 and CDK6, P16INK4 prevents RB phosphor-
ylation, leading to G1-S block. The copy number losses of
CDKN2A and 13q were identiﬁed as potentially poor prognostic
markers in TETs, implying that RB pathway deregulation may
be important in TET pathogenesis [41]. In the same study, IHC
on 132 TETs demonstrated that copy number loss of CDKN2A
correlated with lack of expression of its related protein p16(INK4)
and identiﬁed tumors with poor prognosis. Downregulation of
p16 through promoter methylation has been observed in 3%–13%
of TETs [83, 84]. No P16INK4 mutations have been described in
TETs, whereas gene deletion appears to be related to invasive phe-
notypes in rat models [85]. Furthermore, decreased expression of
the cell cycle proteins p21 and p27 (both CDK inhibitors) is pre-
dictive of a poor response to chemotherapy in T [86].
Oral milciclib maleate (PHA-848125-AC)—an oral, potent
inhibitor of the CDK2/cyclin Two ongoing phase II studies
(clinicaltrials.gov NCT01011439 and NCT01301391) are current-
ly investigating the use of this molecule in pretreated patients
with advanced TETs. At the 2014 ASCO annual meeting, prelim-
inary data were presented regarding patients who received one
prior line of systemic therapy: of 30 patients for whom mature
data were available, 14 cases were successful with a PFS-3 rate of
46.7% (95% CI 28.3% to 65.7%) including PR and with a moder-
ate toxicity proﬁle [59].
Src inhibitors
The SRC family of tyrosine kinases and downstream targets play
a crucial role in thymocyte development. A phase II trial investi-
gated saracatinib (AZD0530), a small-molecule inhibitor of Src,
in patients with previously treated advanced thymic malignan-
cies. A total of 21 patients (14 Ts and 7 TCs) received 175 mg of
saracatinib daily, but the trial was terminated due to a lack of
clinical activity [60].
phosphoinositide-3-kinase pathway
No alterations have been reported in the phosphoinositide-
3-kinase (PI3K)-catalytic subunit (PIK3CA), phosphatase, and
tensin homolog deleted on chromosome 10 (PTEN), protein
kinase B (PKB or AKT1), or mTOR. A phase II study is investi-
gating use of the mTOR inhibitor everolimus in TETs previously
treated with cisplatin-based chemotherapy. At the 50th ASCO
annual meeting, preliminary data were presented from the ﬁrst
enrolled 35 patients in this trial, of whom 25 achieved disease
control as the primary end point: CR in 1 TC, PR in 3 patients
(2 TCs/1T), and SD in 21 patients (16 TCs/5 Ts) [61]. The study
is still ongoing (clinicaltrials.gov NCT02049047).
expert commentary and 5-year view
The rarity and complexity of TETs has hindered investigations
of their causes and slowed the development of advanced and
targeted biological treatments. Despite the lack of valid preclin-
ical models and other challenges faced by these studies, our
general knowledge of the aberrant pathways involved in TETs
development is improving, primarily through insights attained
based on anecdotal clinical responses to targeted therapies. To
date, data indicates that EGFR, KIT, IGF1R, and several VEGF
molecules are overexpressed in TETs. Furthermore, EGFR over-
expression in TETs is associated with higher disease stage, and
IGF1R overexpression carries poor prognostic value. Clinical
data suggest that anti-IGF1R monoclonal antibodies, and inhi-
bitors of angiogenesis, SST receptors, HDAC, mTOR, and CDK
may be potentially useful as targeted biological therapies against
TETs. While many investigations of biological agents have
demonstrated a lack of activity against TETs, the few promising
results—for example, in the studies of antiangiogenesis, mTOR,
and CDK/TrkA inhibitors—are encouraging and support the
continuation of efforts. In upcoming years, we expect that the
completion of ongoing trials and initiation of new studies will
further advance our knowledge of the causes of and genetic
aberrations involved in various types of TETs, leading to devel-
opment and use of biological therapies that will be particularly
useful for managing unresectable cases.
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